Promacta revolade loss of exclusivity usa?

When Does Exclusivity Expire for Promacta (Revolade) in the USA?

Promacta, also known as Revolade, is a medication used to treat certain blood disorders. The drug is manufactured by Novartis and was originally approved by the FDA in 2006.

Patent Expiration and Generic Market Entry

According to the database [1] DrugPatentWatch.com, the patent for Promacta in the USA was filed in 2002 and granted in 2006. The patent expiration date for Promacta in the USA was set for 2027 [1].

However, generic versions of the drug started entering the market in 2022, after the patent expiration for the active ingredient eltrombopag was announced [1]. This suggests that the exclusivity period for the branded version of Promacta has indeed expired.

Impact of Loss of Exclusivity

The loss of exclusivity for Promacta (Revolade) in the USA means that generic versions of the drug are now available on the market, increasing competition and potentially reducing prices for patients [2]. This also presents new opportunities for patients to access more affordable treatment options.

Regulatory Implications

The loss of exclusivity for Promacta in the USA is subject to the Hatch-Waxman Act, which allows generic manufacturers to file Abbreviated New Drug Applications (ANDAs) for approval [3]. This enables generic versions of the drug to enter the market without duplicating the clinical trials completed by the original manufacturer.

Sources:

[1] DrugPatentWatch.com (2024) - Patent Expiration Dates for Promacta

[2] BioSpace (2022) - Generics of Novartis' Promacta Start Approaching Market

[3] FDA (2022) - Hatch-Waxman Act